An Evidence-Based Review of the Cardiovascular Risks of Nonsteroidal Anti-Inflammatory Drugs

American Journal of Cardiology

Volumn 103, Issue 9, 2009, Pages 1227-1237

  Farkouh, Michael E ^a   Greenberg, Bruce P ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MDG Development Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; ETODOLAC; ETORICOXIB; FENOPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LUMIRACOXIB; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PARACETAMOL; PARECOXIB; PHENYLBUTAZONE; PIROXICAM; PLACEBO; ROFECOXIB; SALAZOSULFAPYRIDINE; SULINDAC; TENOXICAM; TOLMETIN; UNINDEXED DRUG; VALDECOXIB;

ADENOMA; ALZHEIMER DISEASE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON POLYP; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONGESTIVE HEART FAILURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART ARREST; HEART DEATH; HEART INFARCTION; HEART PROTECTION; HEARTBURN; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; LUNG EMBOLISM; OSTEOARTHRITIS; PAIN; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; STROKE; SUDDEN DEATH; THROMBOEMBOLISM; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INCIDENCE; MALE; PAIN; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 65249190314     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.01.014     Document Type: Review

References (44)

1. Baron J.A., Sandler R.S., Bresalier R.S., Lanas A., Morton D.G., Riddell R., Iverson E.R., and Demets D.L. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372 (2008) 1756-1764
2. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
3. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal antiinflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. Lancet 370 (2007) 2138-2151
4. Antman E.M., DeMets D., and Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 112 (2005) 759-770
5. Sanmuganathan P.S., Ghahramani P., Jackson P.R., Wallis E.J., and Ramsay L.E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85 (2001) 265-271
6. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., Bierma-Zeinstra S., Brandt K.D., Croft P., Doherty M., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16 (2008) 137-162
7. Chan F.K., Abraham N.S., Scheiman J.M., Laine L., and First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-Inflammatory Drugs and Anti-Platelet Agents. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-Inflammatory Drugs and Anti-Platelet Agents. Am J Gastroenterol 103 (2008) 2908-2918
8. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., et al., VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
9. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 1 (2006) e33
10. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., and Thal L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289 (2003) 2819-2826
11. Cannon C.P., Curtis S.P., FitzGerald G.A., Krum H., Kaur A., Bolognese J.A., Reicin A.S., Bombardier C., Weinblatt M.E., van der H.D., et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368 (2006) 1771-1781
12. Farkouh M.E., Kirshner H., Harrington R.A., Ruland S., Verheugt F.W., Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., et al., TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364 (2004) 675-684
13. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 284 (2000) 1247-1255
14. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., Anderson W.F., Zauber A., Hawk E., and Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
15. White W.B., Faich G., Whelton A., Maurath C., Ridge N.J., Verburg K.M., Geis G.S., and Lefkowith J.B. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 89 (2002) 425-430
16. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
17. Nissen S.E. ADAPT: The wrong way to stop a clinical trial. PLoS Clin Trials 1 (2006) e35
18. Chou R., Helfand R., Peterson K., Dana T., and Roberts C. Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative effectiveness review no. 4. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm Accessed September 30, 2008.
19. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
20. Garcia-Rodriguez L., and Gonzalez-Perez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Medicine 3 (2005) 17
21. Graham D.J., Campen D., Hui R., Spence M., Cheetham C., Levy G., Shoor S., and Ray W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
22. Helin-Salmivaara A., Virtanen A., Vesalainen R., Gronroos J.M., Klaukka T., Idanpaan-Heikkila J.E., and Huupponen R. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 27 (2006) 1657-1663
23. Hippisley-Cox J., and Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330 (2005) 1366
24. Johnsen S.P., Larsson H., Tarone R.E., McLaughlin J.K., Norgard B., Friis S., and Sorensen H.T. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 165 (2005) 978-984
25. Juni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P.A., and Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364 (2004) 2021-2029
26. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., and Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?. Meta-analysis of randomised trials. BMJ 332 (2006) 1302-1308
27. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296 (2006) 1633-1644
28. Salpeter S.R., Gregor P., Ormiston T.M., Whitlock R., Raina P., Thabane L., and Topol E.J. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 119 (2006) 552-559
29. Baigent C., and Patrono C. Selective COX-2 inhibitors: where do we go from here?. Lancet 372 (2008) 1712-1713
30. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., et al., PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885-895
31. Solomon S.D., Pfeffer M.A., McMurray J.J., Fowler R., Finn P., Levin B., Eagle C., Hawk E., Lechuga M., Zauber A.G., et al., APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114 (2006) 1028-1035
32. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., Boyce S.W., and Verburg K.M. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
33. White W.B., West C.R., Borer J.S., Gorelick P.B., Lavange L., Pan S.X., Weiner E., and Verburg K.M. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 99 (2007) 91-98
34. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., Vyas S.N., and FitzGerald G.A. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
35. MacDonald T.M., and Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361 (2003) 573-574
36. Renda G., Tacconelli S., Capone M.L., Sacchetta D., Santarelli F., Sciulli M.G., Zimarino M., Grana M., D'Amelio E., Zurro M., et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 80 (2006) 264-274
37. Gengo F.M., Rubin L., Robson M., Rainka M., Gengo M.F., Mager D.E., and Bates V. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol 48 (2008) 117-122
38. Capone M.L., Sciulli M.G., Tacconelli S., Grana M., Ricciotti E., Renda G., Di Gregorio P., Merciaro G., and Patrignani P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45 (2005) 1295-1301
39. Brune K., Hochberg M., Schiff M., Oldenhof J., Schuller R., and Zlotnick S. The platelet inhibitory effects of the combination of naproxen sodium or acetaminophen with low-dose aspirin. [abstract no. 858]. Arthritis Rheum 59 (2007) S359
40. Farkouh M.E., Greenberg J.D., Jeger R.V., Ramanathan K., Verheugt F.W., Chesebro J.H., Kirshner H., Hochman J.S., Lay C.L., Ruland S., et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 66 (2007) 764-770
41. Capone M.L., Tacconelli S., Sciulli M.G., Grana M., Ricciotti E., Minuz P., Di Gregorio P., Merciaro G., Patrono C., and Patrignani P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109 (2004) 1468-1471
42. Zlotnick S., Oldenhof J., Schuller R., Schiff M., and Hochberg M.C. Effect of over-the-counter doses of naproxen sodium on inhibition of platelet cyclooxygenase-1 in healthy volunteers. [abstract no. P96]. Osteoarthritis Cartilage 14 (2006) S63
43. United States Food and Drug Administration. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. http://www.fda.gov/bbs/topics/news/2004/NEW01122.html Accessed October 25, 2007.
44. MacDonald T.M., Reginster J.Y., Littlejohn T.W., Richard D., Lheritier K., Krammer G., and Rebuli R. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. J Hypertens 26 (2008) 1695-1702